LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

39.31 3.8

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

38.18

Max

39.87

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.4M -81M
EPS	-0.5
Peļņas marža	-1,582.642
Darbinieki	205
EBITDA	-6.8M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+15.04% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	4B 6.2B
Iepriekšējā atvēršanas cena	35.51
Iepriekšējā slēgšanas cena	39.31

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 19. dec. 17:29 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025. g. 19. dec. 16:47 UTC

Galvenie tirgus virzītāji

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025. g. 19. dec. 16:10 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025. g. 19. dec. 22:33 UTC

Peļņas

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025. g. 19. dec. 22:19 UTC

Peļņas

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025. g. 19. dec. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 21:44 UTC

Peļņas

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 21:38 UTC

Peļņas

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025. g. 19. dec. 21:00 UTC

Tirgus saruna

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025. g. 19. dec. 20:23 UTC

Tirgus saruna

Oil Futures End Down Week on Up Note -- Market Talk

2025. g. 19. dec. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025. g. 19. dec. 18:38 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025. g. 19. dec. 18:00 UTC

Tirgus saruna

Peļņas

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025. g. 19. dec. 17:41 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 17:24 UTC

Tirgus saruna

Peļņas

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 19. dec. 16:29 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025. g. 19. dec. 16:20 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025. g. 19. dec. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025. g. 19. dec. 16:18 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025. g. 19. dec. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 16:04 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 15:37 UTC

Tirgus saruna

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

2025. g. 19. dec. 15:21 UTC

Tirgus saruna

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

2025. g. 19. dec. 15:09 UTC

Tirgus saruna

Gold Flat But Set for Weekly Gains -- Market Talk

2025. g. 19. dec. 15:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 19. dec. 15:09 UTC

Peļņas

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

15.04% augšup

Prognoze 12 mēnešiem

Vidējais 45.5 USD 15.04%

Augstākais 67 USD

Zemākais 30 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.